

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	LEX-009DV
First Named Inventor	Lo
Title	Expression and Export of Interferon-Alpha Proteins as Fc Fusion Proteins

J1050 U.S. PTO
09/977034
10/11/01

Respectfully submitted,
Pat R H Waller
Patrick R. H. Waller, Ph.D.
Agent for the Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110

FEE TRANSMITTAL **FY 2002**

Complete if Known

Application Serial Number	Not Yet Assigned
Filing Date	October 11, 2001
First Named Inventor	Lo
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket No.	LEX-009DV

METHOD OF PAYMENT

1. ☒ Payment Enclosed:
☒ Check ☐ Money Order ☐ Other
2. ☒ The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531.
☐ Required Fees (copy of this sheet enclosed).
☒ Additional fee required under 37 CFR 1.16 and 1.17.
☒ Overpayment Credit.
3. ☐ Applicant claims small entity status.

FEE CALCULATION

1. FILING FEE

Large Entity

Fee (\$)	Fee Description	Fee Paid
740	Utility filing fee	740.00
330	Design filing fee	
160	Provisional filing fee	

Number Filed	Number Extra	Rate	Amount
--------------	--------------	------	--------

Total Claims - 20 = x \$ 18.00 =

Independent Claims - 3 = x \$ 84.00 =

☐ Multiple Dependent Claim(s), if any \$280.00 =

TOTAL:
 SMALL ENTITY DISCOUNT:
 SUBTOTAL (1) (\$) 740.00

2. AMENDMENT CLAIM FEES

Claims	Highest No. Previously	Present Extra	Rate	Fee Paid
Remaining After Amend.		Paid For		
Total	-	=	x \$ 18.00 =	
Indep.	-	=	x \$ 84.00 =	
<input type="checkbox"/> First Presentation of Multiple Dep. Claim			+ \$280.00 =	

TOTAL: (\$)
 SMALL ENTITY DISCOUNT: (\$)
 SUBTOTAL (2) (\$)

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid
130	65	Surcharge - late filing fee or oath	
50	25	Surcharge - late provisional filing fee or cover sheet	
130	130	Non-English specification	
2,520	2,520	Request for ex parte reexamination	
110	55	Extension for reply within first month	
400	200	Extension for reply within second month	
920	460	Extension for reply within third month	
1440	720	Extension for reply within fourth month	
1960	980	Extension for reply within fifth month	
320	160	Notice of Appeal	
320	160	Filing a brief in support of an appeal	
280	140	Request for oral hearing	
130	130	Petitions to the Commissioner	
180	180	Submission of Information Disclosure Statement	
740	370	Filing a submission after final rejection (37 CFR 1.129(a))	
740	370	For each additional invention to be examined (37 CFR 1.129(b))	
100	100	Certificate of Correction for applicant's error	

Other fee (Specify)

Other fee (Specify)

SUBTOTAL (3) (\$)

SUBTOTAL (1) 740.00

SUBTOTAL (2)

SUBTOTAL (3)

TOTAL (\$) 740.00

CORRESPONDENCE ADDRESS

Direct all correspondence to:

Patent Administrator
 Testa, Hurwitz & Thibault, LLP
 High Street Tower-125 High Street
 Boston, MA 02110
 Tel. No.: (617) 248-7000
 Fax No.: (617) 248-7100

SIGNATURE BLOCK

Date: October 11, 2001
 Reg. No.: 41,418
 Tel. No.: 617-248-7240
 Fax No.: (617) 248-7100

Respectfully submitted,

Pat R H Wall
 Patrick R.H. Waller, Ph.D.
 Agent for the Applicants
 Testa, Hurwitz & Thibault, LLP
 High Street Tower-125 High Street
 Boston, MA 02110

Express Mail Label No.: EL816677578US

PATENT

Atty. Docket No. LEX-009DV

(4006/20)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Lo et al.

SERIAL NUMBER: Not Yet Assigned
(Divisional of U.S.S.N. 09/575,503)

GROUP NUMBER: Not Yet Assigned

FILING DATE: October 11, 2001

EXAMINER: Not Yet Assigned

TITLE: Expression and Export of Interferon – Alpha Proteins as Fc Fusion Proteins

**REQUEST TO USE COMPUTER READABLE FORM OF SEQUENCE LISTING FROM
ANOTHER APPLICATION**


Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby request that the computer readable copy of the sequence listing be transferred from another application.

Applicants hereby state that the computer readable form of sequence listing in the instant divisional application is identical with that filed in the co-pending parent U.S. Application Serial Number 09/575,503, filed on May 19, 2000. In accordance with 37 CFR 1.821 (e), please use the computer readable form of sequence listing filed in United States Serial Number 09/575,503, for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in the application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally filed specification of the instant application.

Respectfully submitted,



Patrick R.H. Waller, Ph.D.

Agent for the Applicants

Testa, Hurwitz & Thibeault, LLP

High Street Tower

125 High Street

Boston, Massachusetts 02110

Date: October 11, 2001

Reg. 41,418

Tel. No.: (617) 248-7240

Fax: (617) 248-7100

2194494